IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Lifted by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 310 shares of the company’s stock after buying an additional 51 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $172,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Patron Partners LLC increased its stake in shares of IDEXX Laboratories by 2.7% during the 4th quarter. Patron Partners LLC now owns 765 shares of the company’s stock worth $425,000 after purchasing an additional 20 shares during the last quarter. NewEdge Wealth LLC increased its position in IDEXX Laboratories by 3.1% during the fourth quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock worth $366,000 after buying an additional 20 shares during the last quarter. Manchester Capital Management LLC raised its holdings in IDEXX Laboratories by 11.9% during the fourth quarter. Manchester Capital Management LLC now owns 188 shares of the company’s stock valued at $104,000 after buying an additional 20 shares in the last quarter. Phoenix Holdings Ltd. boosted its position in IDEXX Laboratories by 2.8% during the third quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock worth $338,000 after purchasing an additional 21 shares during the period. Finally, BluePath Capital Management LLC lifted its position in IDEXX Laboratories by 1.8% during the 4th quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock worth $663,000 after acquiring an additional 21 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Barclays reduced their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Morgan Stanley lowered their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $580.38.

IDEXX Laboratories Stock Up 0.1 %

Shares of NASDAQ IDXX traded up $0.40 during mid-day trading on Friday, reaching $516.50. 267,200 shares of the company’s stock were exchanged, compared to its average volume of 546,767. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $42.66 billion, a price-to-earnings ratio of 50.00, a PEG ratio of 4.21 and a beta of 1.27. The business has a fifty day simple moving average of $509.96 and a 200 day simple moving average of $522.68.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. The firm had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.